The UK’s MHRA recently published its guidance on its approach to both regulating the use of AI for drug and medical devices, and how it can utilise the technology to improve its regulating
As device developers of all sizes grapple with the updated transition timeline for EU MDR compliance and the recent EU AI Act approval falls short of expectations, the question looms: how can regul
US medical device company HDL Therapeutics is aiming to list on the Nasdaq via a merger with Swiftmerge Acquisition, a special purpose acquisition company (SPAC).
Nerve damage is a recognised side effect of some CAR-T therapies for cancer, and one that could be spotted early using a pen device developed by UK company Manus Neurodyna
